Navigation Links
BioSpecifics Technologies Corp. Announces Launch of XIAPEX® by Pfizer for Treatment of Dupuytren's Contracture in Europe
Date:4/11/2011

LYNBROOK, N.Y., April 11, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that it will receive a $2.5 million milestone payment as a result of the European launch and first commercial sale of XIAPEX (collagenase clostridium histolyticum ) in the United Kingdom, a major European market. Pfizer, Inc. (Pfizer), the EU licensee received approval from the European Medicines Agency (EMA) to market XIAPEX in Europe for the treatment of Dupuytren's contracture, a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers. XIAPEX is the first injectable treatment to be approved in the EU for the treatment of this indication, which affects approximately 13% of the European population. (1)

"This approval is a significant milestone for XIAPEX and we look forward to its commercial success in this important market," commented Thomas L. Wegman, President of BioSpecifics. "We are confident that Pfizer's proven marketing and commercialization capabilities will aid in the success of the launch of XIAPEX in the European marketplace. We are very excited to see the results of our hard work in developing this clinical indication, now that it's available to more patients and physicians who can benefit from it."

BioSpecifics' strategic partner, Auxilium Pharmaceuticals, Inc. (Auxilium), markets injectable collagenase for Dupuytren's contracture in the United States under the trade name XIAFLEX®, and sub-licensed Pfizer the rights to market it for Dupuytren's contracture and Peyronie's disease in 27 member countries of the European Union and 19 other European and Eurasian countries.

Under the terms of the strategic alliance agreement between BioSpecifics and Auxilium, BioSpecifics will receive 8.5% of each additional $7.5 million milestone payment ($30 million in aggregate) made as a result of the first commercial sale in each additional major European market; France, Italy, Germany and Spain. In addition BioSpecifics will receive 8.5% of all additional sublicense income Auxilium receives from Pfizer. BioSpecifics will also continue to receive low double-digit royalties on sales, independent of indication, territory, sales volume and whether Auxilium or Pfizer sells the product. In addition, BioSpecifics will receive a markup on the cost of goods sold.

Further details and product information will be available in the European Public Assessment Report on the web site of the European Medicines Agency at www.emea.europa.eu.

About Dupuytren's Contracture

Dupuytren's contracture is caused by an abnormal accumulation of collagen in the palm of the hand characterized by the formation of nodules or lumps in the early stages. As the disease progresses, a cord is formed and the fingers may become progressively contracted.

About XIAPEX (Collagenase clostridium histolyticum)

Collagenase clostridium histolyticum is a combination of two purified collagenases (collagenase is an enzyme capable of breaking down collagen), derived from the bacterium Clostridium histolyticum. It is the first pharmacological treatment to be developed for Dupuytren's contracture and may be an alternative to invasive and often complicated surgery for patients in the EU. Collagenase clostridium histolyticum is administered by local injection directly into the Dupuytren's cord - a procedure which can be carried out in an outpatient setting. It works by breaking down the structure of the cord and, 24 hours after injection, a finger extension procedure can be carried out as necessary to break the cord and allow extension of the finger. If contracture remains four weeks after treatment, another injection can be administered into the same cord, and the finger extension procedure can be carried out again. Injections and finger extension procedures may be administered up to three times per cord, at approximately four-week intervals.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX® in Europe and have announced European regulatory approval and the first commercial sale in the United Kingdom. More information about BioSpecifics may be found on its website at www.biospecifics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statements regarding BioSpecifics' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes," "expects," "anticipates," "plans," "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the statements made by BioSpecifics regarding the success of the commercialization of XIAPEX in Europe by Pfizer; the timing and amount of milestone and royalty payments due to BioSpecifics from Auxilium resulting from the commercialization of XIAPEX in Europe by Pfizer; and other risk factors identified in BioSpecifics' Form 10-K for the year ended December 31, 2010 and its reports on Form 8-K filed with the SEC. All forward-looking statements included in this press release are made as of the date hereof, and BioSpecifics assumes no obligation to update these forward-looking statements.

(1) Source: Auxilium Pharmaceuticals


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
2. BioSpecifics Technologies Corp. Amends Its Rights Agreement
3. BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. BioSpecifics Technologies Corp. Awarded Two Qualifying Therapeutic Discovery Project Grants
5. BioSpecifics Technologies Corp. to Present at BioCentury Newsmakers in the Biotech Industry Conference
6. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2010 Financial Results on August 6, 2010
8. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
9. BioSpecifics Technologies Corp. to Present at Jefferies & Company 2010 Global Life Sciences Conference
10. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2010 Financial Results on May 7, 2010
11. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... INC. (NasdaqCM: PDEX) today announced financial results for its fiscal ... filed its Quarterly Report on Form 10-Q for the second ... Commission today. --> --> ... --> Net sales for the three months ended ... million from $2.8 million for the three months ended December ...
(Date:2/11/2016)... DUNKIRK, N.Y. , Feb. 11, 2016  Governor ... Athenex that will create 1,400 jobs throughout ... by a partnership with the SUNY Polytechnic Institute, includes ... the Conventus Building in Buffalo , ... square foot manufacturing facility in Dunkirk ...
(Date:2/11/2016)...  MiMedx Group, Inc. (NASDAQ: MDXG ), the ... other birth tissues, human skin and bone, and patent-protected ... products and therapies, announced today that it will present ... in New York , NY.  Parker ... Senken , Chief Financial Officer and Chris Cashman ...
Breaking Medicine Technology:
(Date:2/12/2016)... , ... February 12, 2016 , ... Each year, the ... be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists ... new therapy products in action, learn more about their chosen field and network with ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology and information ... ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards for both ... and Awards Gala on March 15, 2016 at the Westin Peachtree Plaza, Atlanta. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Every winter, someone is killed, injured or ... West Penn Burn Center, part of the Allegheny Health Network, has partnered with ... the “Space Heaters Need Space” campaign. , “Space Heaters Need Space” aims ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a family owned ... Texas, is launching a cooperative charity drive with the Tarrant Area Food Bank in ... 50,000 individuals and families in need, the Tarrant County Food Bank offers hope and ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... of the Pittsburgh metro area, celebrates the beginning of the latest charity campaign ... develop social skills through art. Donations to this worthy cause are currently being ...
Breaking Medicine News(10 mins):